Mainstay hopes US regulator will approve back pain device in 2020
Company says it will need to raise €45 million if it gets FDA green light
Mainstay Medical has said it will need to raise about $50 million (€45 million) if it secures approval from drug regulators to launch its chronic back pain treatment in America
Dublin stock market-listed Mainstay has submitted its treatment for pre-market approval by the US Food & Drug Administration (FDA) and is hopeful of securing the green light late next year.
Jason Hannon, Mainstay’s chief executive, said data submitted to the FDA based on patients using its treatment...
Subscribe from just 1€
Choose the subscription that is right for you
For the first month
€19.99 Monthly ThereafterSubscribe today
For the first year
€199.99 annually thereafterSubscribe today
For the first 90 days
€55.00 quarterly ThereafterSubscribe today
These offers are not available for current subscribers. Offers and pricing are subject to change without notice.
Terms & Conditions Apply